Drug-induced hepatotoxicity (DIH) is a common adverse event that is associated with both antiretroviral (ARV) and anti-tuberculosis drugs (ATD). Moreover, the genetic variations predisposing ARV- and ARV-ATD-induced liver toxicity in African populations are not well investigated, despite the two diseases being the major global health problems in sub-Saharan Africa. We performed a genome-wide association study (GWAS) and replication study to identify the genetic variants linked to the risk of developing DIH due to ARV drugs alone, and ARV-ATD co-treatment in Ethiopian HIV-positive patients. Treatment-naïve newly diagnosed HIV patients (n = 719) with or without tuberculosis (TB) co-infection were enrolled prospectively and received efavirenz-based ARV therapy with or without rifampicin-based short course ATD, respectively. Whole-genome genotyping was performed by using the Illumina Omni Express Exome Bead Chip genotyping array with 951,117 single nucleotide polymorphisms (SNPs) on a total of 41 cases of DIH, and 452 people without DIH (treatment tolerants). The replication study was carried out for 100 SNPs with the lowest p-values (top SNPs) by using an independent cohort consisting of 18 DIH cases and 208 treatment tolerants. We identified a missense SNP rs199650082 (2756G→A, R919Q, p = 1.4 × 10−6, odds ratio [OR] = 18.2, 95% confidence interval [CI] = 7.1–46.9) in an endoplasmic reticulum to the nucleus signaling-1 (ERN1) gene on chromosome 17 to be associated with DIH in the ARV-only cohort. In the ARV-ATD co-treatment groups, rs4842407, a long intergenic noncoding RNAs (lincRNAs) transcript variant on chromosome 12, was associated with DIH (p = 5.3 × 10−7, OR = 5.4, 95% CI = 2.8–10.3). These genetic variants that are putatively associated with DIH due to ARV drugs alone and ARV-ATD co-treatment establish a foundation for future personalized medicine in people with HIV and TB and call for larger studies in independent populations.
Get full access to this article
View all access options for this article.
References
1.
AithalGP, and GroveJI. (2015). Genome-wide association studies in drug-induced liver injury: Step change in understanding the pathogenesis. Semin Liver Dis, 35, 421–431.
2.
AithalGP, WatkinsPB, AndradeRJ, et al. (2011). Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 89, 806–815.
3.
AklilluE, DjordjevicN, CarrilloJA, MakonnenE, BertilssonL, and Ingelman-SundbergM. (2014). High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS, 18, 446–453.
4.
AklilluE, HabtewoldA, NgaimisiE, et al. (2016). SLCO1B1 gene variations among Tanzanians, Ethiopians, and Europeans: Relevance for African and worldwide precision medicine. OMICS, 20, 538–545.
5.
AklilluE, PerssonI, BertilssonL, JohanssonI, RodriguesF, and Ingelman-SundbergM. (1996). Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther, 278, 441–446.
6.
Araujo-MarizC, LopesEP, Acioli-SantosB, et al. (2016). Hepatotoxicity during treatment for tuberculosis in people living with HIV/AIDS. PLoS One, 11, e0157725.
7.
BarrettJC, FryB, MallerJ, and DalyMJ. (2005). Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263–265.
8.
CaiL, ChangH, FangY, and LiG. (2016). A comprehensive characterization of the function of lincRNAs in transcriptional regulation through long-range chromatin interactions. Sci Rep, 6, 36572.
9.
CampbellMC, and TishkoffSA. (2008). African genetic diversity: Implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet, 9, 403–433.
10.
ChenL, XuS, LiuL, et al. (2014a). Cab45S inhibits the ER stress-induced IRE1-JNK pathway and apoptosis via GRP78/BiP. Cell Death Dis, 5, e1219.
11.
ChenS, MelchiorWBJr, and GuoL. (2014b). Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 32, 83–104.
12.
DahlinA, LitonjuaA, LimaJJ, et al. (2015). Genome-wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. PLoS One, 10, e0129385.
DalyAK. (2016). Are polymorphisms in genes relevant to drug disposition predictors of susceptibility to drug-induced liver injury?. Pharm Res. DOI: 10/1007/s11095-016-2091-1. [Epub ahead of print]
15.
DalyAK, DonaldsonPT, BhatnagarP, et al. (2009). HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet, 41, 816–819.
16.
DananG, and BenichouC. (1993). Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol, 46, 1323–1330.
17.
de BakkerPI, FerreiraMA, JiaX, NealeBM, RaychaudhuriS, and VoightBF. (2008). Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet, 17, R122–R128.
18.
DevlinB, and RoederK. (1999). Genomic control for association studies. Biometrics, 55, 997–1004.
19.
Ellinger-ZiegelbauerH, BrownK, KellyK, and SiebenlistU. (1997). Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative. J Biol Chem, 272, 2668–2674.
20.
ElsharkawyAM, SchwabU, McCarronB, et al. (2013). Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. J Clin Virol, 58, 331–333.
21.
FinkDL, and BlochE. (2013). Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: The importance of routine monitoring. Int J STD AIDS, 24, 831–833.
22.
FontanaRJ. (2014). Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology, 146, 914–928.e911.
23.
GebeyehuE, EngidaworkE, BijnsdorpA, AminyA, DiczfalusyU, and AklilluE. (2011). Sex and CYP3A5 genotype influence total CYP3A activity: High CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J, 11, 130–137.
24.
HeY, WuYT, HuangC, et al. (2014). Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochim Biophys Acta, 1842, 2204–2215.
25.
HiranoT, YoshikawaR, HaradaH, HaradaY, IshidaA, and YamazakiT. (2015). Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer, 14, 90.
26.
HuangYS. (2014). Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc, 77, 169–173.
27.
ItzhakD, BrightM, McAndrewP, et al. (2014). Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1alpha. BMC Biochem, 15, 3.
28.
JonesM, and NunezM. (2012). Liver toxicity of antiretroviral drugs. Semin Liver Dis, 32, 167–176.
29.
KimSH, KimSH, LeeJH, et al. (2015). Superoxide dismutase gene (SOD1, SOD2, and SOD3) polymorphisms and antituberculosis drug-induced hepatitis. Allergy Asthma Immunol Res, 7, 88–91.
30.
LamarZS, and NunezM. (2011). Higher risk of severe drug-induced liver injury among Hispanic HIV-infected patients after initiation of highly active antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic), 10, 183–186.
31.
MeliaT, HaoP, YilmazF, and WaxmanDJ. (2016). Hepatic long intergenic noncoding RNAs: High promoter conservation and dynamic, sex-dependent transcriptional regulation by growth hormone. Mol Cell Biol, 36, 50–69.
32.
MikusM, DrobinK, GryM, et al. (2016). Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver Int, 37, 132–140.
33.
MugusiS, NgaimisiE, JanabiM, et al. (2012). Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One, 7, e40180.
34.
NgaimisiE, HabtewoldA, MinziO, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One, 8, e67946.
35.
NunezM. (2010). Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology, 52, 1143–1155.
36.
OhnishiY, TanakaT, OzakiK, YamadaR, SuzukiH, and NakamuraY. (2001). A high-throughput SNP typing system for genome-wide association studies. J Hum Genet, 46, 471–477.
37.
PeprahE, XuH, Tekola-AyeleF, and RoyalCD. (2015). Genome-wide association studies in Africans and African Americans: Expanding the framework of the genomics of human traits and disease. Public Health Genomics, 18, 40–51.
38.
PetrosZ, LeeMM, TakahashiA, et al. (2016). Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics, 17, 755.
39.
PriceAL, PattersonNJ, PlengeRM, WeinblattME, ShadickNA, and ReichD. (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet, 38, 904–909.
40.
PurcellS, NealeB, Todd-BrownK, et al. (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet, 81, 559–575.
41.
RadtkeI, MullighanCG, IshiiM, et al. (2009). Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A, 106, 12944–12949.
42.
ReislerRB, HanC, BurmanWJ, TedaldiEM, and NeatonJD. (2003). Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr, 34, 379–386.
43.
RitchieMD, HaasDW, MotsingerAA, et al. (2006). Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis, 43, 779–782.
44.
ShiX, SunM, LiuH, YaoY, and SongY. (2013). Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett, 339, 159–166.
45.
SokoND, MasimirembwaC, and DandaraC. (2016). Pharmacogenomics of Rosuvastatin: A glocal (global+local) African perspective and expert review on a statin drug. OMICS, 20, 498–509.
46.
TeoY, SmallK, and KwiatkowskiD. (2010). Methodological challenges of genome-wide association analysis in Africa. Nat Rev Genet, 11, 149–160.
47.
ThulinP, NordahlG, GryM, et al. (2014). Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int, 34, 367–378.
48.
TirasophonW, WelihindaAA, and KaufmanRJ. (1998). A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. Genes Dev, 12, 1812–1824.
49.
TurkovaA, BallC, Gilmour-WhiteS, RelaM, and Mieli-VerganiG. (2009). A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation. J Antimicrob Chemother, 63, 623–625.
50.
UgiagbeRA, MaluAO, BojuwoyeBJ, and OnunuAN. (2012). Incidence of hepatotoxicity of highly active antiretroviral therapy in a tertiary health centre in Nigeria. Niger Postgrad Med J, 19, 127–132.
UrbanTJ, DalyAK, and AithalGP. (2014). Genetic basis of drug-induced liver injury: Present and future. Semin Liver Dis, 34, 123–133.
53.
Van SummerenA, RenesJ, van DelftJH, KleinjansJC, and MarimanEC. (2012). Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol In Vitro, 26, 373–385.
YimerG, AderayeG, AmogneW, et al. (2008). Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS One, 3, e1809.
56.
YimerG, AmogneW, HabtewoldA, et al. (2012). High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: A prospective cohort study. Pharmacogenomics J, 12, 499–506.
57.
YimerG, GryM, AmogneW, et al. (2014). Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: A prospective four arm observational study in Ethiopian patients. PLoS One, 9, e94271.
58.
YimerG, UedaN, HabtewoldA, et al. (2011). Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One, 6, e27810.
59.
YuF, LuZ, ChenB, DongP, and ZhengJ. (2016). Identification of a novel lincRNA-p21-miR-181b-PTEN signaling cascade in liver fibrosis. Mediators Inflamm, 2016, 9856538.
60.
ZhengJ, DongP, MaoY, et al. (2015). lincRNA-p21 inhibits hepatic stellate cell activation and liver fibrogenesis via p21. FEBS J, 282, 4810–4821.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
